Effects of a Selective CD11b/CD18 Antagonist and Recombinant Human Tissue Plasminogen Activator Treatment Alone and in Combination in a Rat Embolic Model of Stroke

Background and Purpose— We evaluated the neuroprotective effect of UK-279,276 (also referred to as recombinant neutrophil inhibitory factor), a selective CD11b/CD18 antagonist, in combination with thrombolytic therapy on focal cerebral ischemia. Methods— Male Wistar rats (n=88) were subjected to embolic middle cerebral artery occlusion. Animals were randomly assigned to the following groups (n=11 in each group): vehicle treatment alone at 2 or 4 hours, UK-279,276 treatment alone at 2 or 4 hours, recombinant human tissue plasminogen activator (rhtPA) treatment alone at 2 or 4 hours, or the combination of UK-279,276 and rhtPA at 2 or 4 hours. Infarct volume, neurological function, hemorrhagic transformation, neutrophil accumulation, and parenchymal fibrin deposition were measured 7 days after middle cerebral artery occlusion. Results— Treatment with UK-279,276 significantly (P <0.05) improved neurological severity scores, an index of neurological functional deficit, but had no effect on infarct volume compared with vehicle-treated animals. Treatment with rhtPA alone at 2 but not 4 hours significantly (P <0.05) reduced infarct volume and improved neurological function compared with vehicle-treated animals. Combination treatment with UK-279,276 and rhtPA at 2 or 4 hours significantly (P <0.01) reduced infarct volume and enhanced recovery of neurological function compared with control. Neutrophil accumulation and fibrin deposition in the brain parenchyma of combination-treated rats at 2 and 4 hours after stroke were significantly reduced (P <0.05) compared with corresponding vehicle-treated control groups. The neuroprotective effect of the combined treatments was superior to the additive effects from each treatment of rhtPA or UK-279,276 alone. Conclusions— These data suggest that the combination treatment with UK-279,276 and rhtPA may extend the window of thrombolytic therapy for the acute treatment of stroke.

[1]  P. Kochanek,et al.  Polymorphonuclear Leukocytes and Monocytes/Macrophages in the Pathogenesis of Cerebral Ischemia and Stroke , 1992, Stroke.

[2]  E. Connolly,et al.  CD18-mediated neutrophil recruitment contributes to the pathogenesis of reperfused but not nonreperfused stroke. , 1999, Stroke.

[3]  M. Chopp,et al.  Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. , 1999, Stroke.

[4]  M. Chopp,et al.  Measurement of myeloperoxidase immunoreactive cells in ischemic brain after transient middle cerebral artery occlusion in the rat , 1997 .

[5]  M. Chopp,et al.  Therapeutic Benefit of Intravenous Administration of Bone Marrow Stromal Cells After Cerebral Ischemia in Rats , 2001, Stroke.

[6]  P. Muchowski,et al.  Functional interaction between the integrin antagonist neutrophil inhibitory factor and the I domain of CD11b/CD18. , 1995, The Journal of Biological Chemistry.

[7]  M. Chopp,et al.  Anti‐ICAM‐1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat , 1994, Neurology.

[8]  S. Diamond,et al.  Neutrophil Enhancement of Fibrin Deposition Under Flow Through Platelet-Dependent and -Independent Mechanisms , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[9]  Timothy Schallert,et al.  Seizures and recovery from experimental brain damage , 1988, Experimental Neurology.

[10]  W C Jean,et al.  Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. , 1998, Neurosurgery.

[11]  M Chopp,et al.  Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat , 1999, Neurology.

[12]  V. Fried,et al.  A hookworm glycoprotein that inhibits neutrophil function is a ligand of the integrin CD11b/CD18. , 1994, The Journal of biological chemistry.

[13]  W. Hacke,et al.  Hemorrhagic Transformation of Ischemic Brain Tissue: Asymptomatic or Symptomatic? , 2001, Stroke.

[14]  T. Springer,et al.  Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. , 1995, Annual review of physiology.

[15]  L. Iversen,et al.  Heparin-binding protein (HBP/CAP37): A missing link in neutrophil-evoked alteration of vascular permeability , 2001, Nature Medicine.

[16]  K. Becker.  Inflammation and acute stroke. , 1998, Current opinion in neurology.

[17]  Michael Chopp,et al.  Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat , 1998, Brain Research.

[18]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[19]  J. Zivin.  Thrombolytic stroke therapy , 1999, Neurology.

[20]  E. Nussbaum,et al.  Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. , 1998, Neurosurgery.

[21]  Michael Chopp,et al.  Postischemic treatment (2–4 h) with anti-CD11b and anti-CD18 monoclonal antibodies are neuroprotective after transient (2 h) focal cerebral ischemia in the rat , 1995, Brain Research.

[22]  G. D. del Zoppo,et al.  Advances in the vascular pathophysiology of ischemic stroke. , 2000, Thrombosis research.

[23]  M. Chopp,et al.  Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion , 2001, Brain Research.

[24]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[25]  J. Grotta.  Neuroprotection is unlikely to be effective in humans using current trial designs. , 2002, Stroke.

[26]  R. Bartus,et al.  The Role of Leukocytes Following Cerebral Ischemia: Pathogenic Variable or Bystander Reaction to Emerging Infarct? , 2002, Experimental Neurology.

[27]  D C Rogers,et al.  To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents? , 1998, Trends in pharmacological sciences.

[28]  P. Kochanek,et al.  Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period. , 1986, Stroke.

[29]  R. Rothlein,et al.  Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy , 1995, Neurology.

[30]  D. L. Griffith,et al.  Solvent-accessible Residues on the Metal Ion-dependent Adhesion Site Face of Integrin CR3 Mediate Its Binding to the Neutrophil Inhibitory Factor* , 1996, The Journal of Biological Chemistry.

[31]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[32]  Michael Chopp,et al.  A rat model of focal embolic cerebral ischemia , 1997, Brain Research.

[33]  M. Chopp,et al.  The clot thickens--thrombolysis and combination therapies. , 1999, Acta neurochirurgica. Supplement.